From so simple a beginning…

In 1980, the commercial potential of academic research in the US was harnessed and revolutionized by the passage of the Bayh-Dole Act that allowed university researchers to file patents and own their inventions and universities to reap the financial benefits of their discoveries. One of the most striking long-term products of that act was my [...]

Continue reading...

Since we are on the contentious subject of drugs and patents, it is worth pointing to another lively debate that has been going on in the blogosphere. In a nutshell, this is what it is about; Merck has a bestselling anti-HIV drug named Efavirenz. They offered to sell it to Brazil at a reduced price. [...]

Continue reading...